A new chapter for Medisca: Sanjay D. Goorachurn appointed as Chief Executive Officer
Medisca Opens MAZ® Lab in Arizona: An Innovation and Customer Resource Center
Medisca Takes Steps to Protect its Innovative Technologies
MONTREAL--(BUSINESS WIRE)--In 2018, Medisca, a global leader in pharmaceutical compounding and personalized medicine, partnered with the Université Laval Faculty of Medicine located in Quebec, Canada. The commitment included funding the establishment of a Chair in Educational Leadership in Chronic Pain Treatment, donating $500,000 to the initiative. Five years later, Medisca is a proud founding partner of the collaborative success of the Université Laval’s Chair in Educational Leadership in Chronic Pain Treatment-Medisca, Dr. Anne Marie Pinard, MD FRCPC, M.(Ed.), and the Quebec Pain Research Network.
Medisca Expands Strategic Partnerships to Drive Patient Access to Critical Medications
PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca, a global company offering pharmaceutical compounding products and services, mixing technology, manufacturing, education services and more, announces plans to lease a standalone 60,000 square foot building to consolidate repackaging and distribution operations in Plattsburgh, NY under one roof.
MONTREAL--(BUSINESS WIRE)--After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning that reflects a journey of growth, diversification, and opportunity. Founded in 1989 as a small business with a handful of employees, Medisca has expanded into a global corporation with strategic partners in education, manufacturing, supply chain, and analytical testing that deliver customized solutions with an unwavering commitment to quality and innovation.
MONTREAL--(BUSINESS WIRE)--On May 31, 2022, Medisca, a global supplier of pharmaceutical compounding products, acquired DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.
As biopharma industry watchers wait to see whether Keytruda will hit its goal as a postsurgery treatment in early lung cancer patients with high tumor expressions of the PD-L1 biomarker, Merck & Co. is rolling out new data to show the drug’s benefits across other patient groups.
MASCOT, Australia--(BUSINESS WIRE)--Over the last several months, Medisca Australia along with other industry leaders have been actively putting forward to the Australian Pharmaceutical Formulary & Handbook (APF), scientific rationale for longer expiry dates for compounded preparations. Medisca is now pleased to see the efforts of the compounding community come to fruition.